Insmed (INSM) After Insider Selling And Brensocatib Hopes What Does Valuation Say

Insmed (INSM) is in focus after Chair and CEO William Lewis exercised stock options for 10,699 shares, then sold the same number in open market transactions under a pre-set Rule 10b5-1 trading plan.

See our latest analysis for Insmed.

At a share price of US$115.61, Insmed has had a 30 day share price return of 18.15%. Its year to date share price return is down 34.73%, while the 1 year total shareholder return of 17.75% and 3 year total shareholder return of more than 4x suggest longer term holders have still seen strong gains. This can shape how the market interprets insider trades like Lewis’s recent sale.

If this kind of move has you thinking about where else growth stories could emerge in healthcare, it may be worth checking a screener of 41 healthcare AI stocks as a starting list of ideas.

After a sharp rebound and fresh insider selling, Insmed now sits at a level where upside potential and execution risks feel more finely balanced. Do the current numbers still tilt the risk reward in favour of new buyers?

Most Popular Narrative: 41.4% Undervalued

Against Insmed's last close of US$115.61, the most followed narrative anchors on a fair value of about US$197, which implies a sizable valuation gap built on future product launches and margin recovery.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Read the complete narrative.

Want to see what sits behind that confidence in Insmed? The narrative focuses on expectations for rapid revenue expansion, a sharp swing from heavy losses and a future earnings multiple that is usually reserved for market leaders. Curious which specific growth and margin assumptions would need to occur for that fair value to hold?

Result: Fair Value of $197.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in Insmed also need to weigh risks around potential FDA review delays and payer pushback, which could slow brensocatib uptake and challenge the current narrative.

Find out about the key risks to this Insmed narrative.

Another View on Insmed’s Valuation

The narrative around Insmed leans heavily on analyst targets and future earnings, but our DCF model tells an even more aggressive story. On that framework, Insmed at $115.61 trades at a steep 69.3% discount to an estimated fair value of $377. This raises a simple question: are the cash flow assumptions too rich, or is the market too cautious?

Before leaning on those numbers, it is worth understanding how the SWS DCF model gets to that $377 figure and which inputs matter most for Insmed, from revenue growth to long term margins and reinvestment needs, Look into how the SWS DCF model arrives at its fair value.

Next Steps

If the mix of optimism and concern around Insmed leaves you undecided, now is the time to examine the underlying data and stress test the assumptions for yourself, then weigh them up against the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Insmed?

Before moving on from Insmed, give yourself a broader watchlist by lining up a few fresh stock ideas that match the kind of opportunities you care about most.

• Spot potential bargains early by scanning screener containing 19 high quality undiscovered gems that combine strong fundamentals with limited analyst attention.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (47 results) to find companies with resilient finances and consistent fundamentals.
• Dial back portfolio stress by filtering for 78 resilient stocks with low risk scores that keep volatility and risk scores in check while still offering room for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com